Table 2 The number of patients with available results of CD2 and CD25 expression in patients with different entities of MC diseases is depicted in Fig. 1.

From: Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis

 

Cutaneous mastocytosis (CM)

Indolent systemic mastocytosis (ISM)

Smoldering systemic mastocytosis (SSM)

Advanced systemic mastocytosis (advSM)

CD2- CD25+ MC

19

290

14

134

CD2+ CD25+ MC

78

1232

31

160

CD2+ CD25- MC

6

15

1

4

CD2- CD25- MC

120

58

2

15

  1. Absolute number of patients with mastocytosis and available results of CD2 and CD25 expression, including cutaneous mastocytosis (CM), indolent systemic mastocytosis (ISM), smoldering systemic mastocytosis (SSM), and advanced systemic mastocytosis (advSM). In 1232 of 1595 patients (77.24%) with ISM, MC expressed both CD2 and CD25, this was the case in only 160 of 313 patients (51.12%) with advSM, whereas in this disease entity 134 of 313 patients (42.81%) did not express CD2 but still expressed CD25.
  2. MC mast cells.
Back to article page